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www.kidney-international.org l e t t e r s to the ed i to rThere is little evidence that
the endothelial glycocalyxOPENhas a specific role in glomerular
permeability of albumin
To the editor: It is not commonly appreciated that the most
accurate quantitative measure of the interaction of glycos-
aminoglycan chains (such as in syndecans) with each other or
with albumin is through the analysis of their equilibrium
thermodynamic interactions.1,2 There are many ways to do
this, say through osmotic pressure analysis. These studies
have, for over 70 years, shown that the interaction is not
charged-based but one of steric exclusion under
physiological conditions. This immediately tells you that
charge selectivity, which has been proposed as a major force
governing transglomerular transport of albumin, is a flawed
concept. This has been shown now in many studies,
particularly in the reanalysis of the work of Haraldsson
et al. and Deen.2 I would encourage any reader interested in
this area to read these critiques and the reexamination of
the data. It is also salutary to note that if such an
extraordinary force existed it would have been recognized
in the general scientific literature; absolutely no recognition,
outside nephrology, has ever been made.
There are still deniers of the lack of charge selectivity,
although where this may be operating has been a moving
target. In the study by Ramnath et al.,3 the mantle has been
assigned to the endothelial glycocalyx. With all the
controversy of the overturning of the charge selectivity
concept (once a basic tenet in nephrology), anyone would
have to be concerned that there still remain research groups
purely devoted to it and the fact that the glomerular filter
offers an extremely restrictive filter to albumin. Ramnath
et al.3 feel justified that an increase of 4.9-fold in albumin
urinary excretion in 8-week post-streptozotocin diabetic
mice can be explained by a 2-fold increase in glomerular
permeability for albumin as measured in isolated glomeruli
whose syndecan-4 has been shed by a matrix
metalloproteinase; these changes can be reversed by
treatment with inhibitors to the matrix metalloproteinase.
On reading this work, serious ambiguities in interpretation
arise from the following:
(i) There is no accounting for tubular uptake of the filtered
albumin. The influence of a 2-fold increase in albumin
permeability will be reduced and therefore become less of
a quantitative explanation for the 4.9-fold increase in
albumin excretion. This clearly diminishes the putative
role of the glycocalyx and raises doubt as to the site of
action of the matrix metalloproteinase inhibitor.
(ii) It is universally accepted that increments in albumin
excretion in diabetes occur independently of nonspecific
changes in the glomerular filter as measured byKidney International (2020) 97, 1057–1060glomerular permeability of dextrans and ficolls. In the
current study, Ramanth et al.3 do not distinguish whether
changes in glomerular permeability are the result of
nonspecific or specific alterations to albumin
permeability.
(iii) As explained in a previous letter,2 this group does not
measure albumin permeability. They measure a
permeability function as well as an albumin-albumin
diffusional exchange function, which is not measured
in any other studies on glomerular permeability or
clearance and has no physiological relevance. Therefore,
the changes they measure may not have anything to do
with glomerular permeability.
(iv) This group is simply dismissive4 of important
experimental 2-photon data that show that the
glomerular sieving coefficient of albumin is governed
by size alone; they have not recognized that the 2-
photon system can accurately provide time-
independent glomerular-sieving coefficient of dextrans
of known glomerular-sieving coefficients.2
1. Comper WD. Glomerular permeability changes of albumin in isolated
glomeruli do not mimic changes in albumin excretion in vivo in diseased
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Elsevier Inc. All rights reserved.The authors reply: We write in response to the
letter entitled “There is Little Evidence That the
Endothelial Glycocalyx Has a Specific Role in
Glomerular Permeability of Albumin,”1 in reference
to our original publication.2 The title of the letter is very
misleading. It represents only the opinion of this author
and is diametrically opposed to the data presented in our
paper and an accumulating body of evidence including
in vivo multiphoton measurements.3 This author’s claims
are not supported by experimental observations, and we
and others have addressed them extensively including in a
response4 to a previous similar letter. It is curious that the
major focus of the letter seems to be on charge selectivity
when charge is not mentioned in our article.1057
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3. Butler MJ, Ramnath R, Kadoya H, et al. Aldosterone induces albuminuria
via matrix metalloproteinase-dependent damage of the endothelial
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vacuoles are a generic toxic
manifestation and not particularly
associated with agrochemicals
and heavy metal toxicity
or specific to a disease
To the editor: I congratulate Vervaet et al. for their article
containing excellent pictures of tubular cells.1 However, the
acronym used, CINAC (chronic interstitial nephritis in
agricultural communities), is misleading; persons not living
in agricultural regions and not exposed to agriculture or
agrochemicals can also develop the same chronic kidney
disease of unknown etiology, which stigmatizes them.2
Lysosomal organelles facilitate cellular metabolism,
degradation of macromolecules, recycling, and redox
regulation, which maintain cell survival.3 Lysosome
tubulopathy includes hereditary and acquired forms. Genetic
abnormalities of lysosomal organelles cause life-threatening
storage disorders,3 whereas acquired lysosomopathies
manifest as generic tubulointerstitial nephropathies.
Once lysosome membranes are damaged, they release
chemical irritants, enzymes, and proteins into cytoplasm,
causing cellular disruptions and even apoptosis. In acquired
lysosomal diseases, toxic tubular pathologies are the final
common pathway but are not specific to particular toxins,
agrochemicals, or diseases.
Using ultrastructural studies, lysosomal tubulopathies have
been reported in many common and rare diseases.4 Such
ultrastructural studies report similar manifestation of1058lysosomal vacuoles. Metabolically, highly active tubular cells
react to neutralize toxins so, unsurprisingly, manifesting
abnormalities are similar, representing lysosomopathies of
toxic tubular cell damage. However, these do not point to
any particular causative factor, including agrochemicals, and
are not novel findings.
As noted in the article,1 such vacuoles have been reported after
exposure to many nephrotoxins, including antibiotics and
antirejection agents. Reported lysosomal manifestations,
including vacuolation,1 are nonspecific and the findings are too
preliminary and overly theoretical to tie to agrochemicals, as
suggested. I suggest that the reported findings are speculative
and not novel or confirmatory of any particular cause.
1. Vervaet BA, Nast CC, Jayasumana C, et al. Chronic interstitial nephritis in
agricultural communities is a toxin-induced proximal tubular
nephropathy. Kidney Int. 2020;97:350–369.
2. Ileperuma O, Weeraratne S, Wimalawansa SJ. Acronyms, CINAC, ACN,
KDUCAL or NUCAL and so on are inappropriate to use for describing
CKDu. J Epidemiol Community Health. 2018;72:967–968.
3. Coutinho MF, Alves S. From rare to common and back again: 60 years of
lysosomal dysfunction. Mol Genet Metab. 2016;117:53–65.
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pathogenesis of kidney diseases. Pediatr Nephrol. 2014;29:2253–2261.
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Elsevier Inc. All rights reserved.The authors reply: We thank Dr. Wimalawansa1
for the interest in our work2 and appreciate the
critical remarks.
With respect to our proximal tubular histo-
pathological observations, in particular the presence of
enlarged dysmorphic lysosomes containing dispersed dark
aggregates, we emphasize that they are novel in chronic
interstitial nephritis in agricultural communities (CINAC)/
chronic kidney disease of unknown etiology (CKDu) and
several toxic nephropathies, including transplant patients
on calcineurin inhibitor therapy.2 To the best of our
knowledge, electron microscopic (EM) images of similar
aberrant lysosomes have only been reported for light
chain disease by Herrera et al., which we independently
confirmed.3 The EM lysosomal phenotype we report is
unquestionably distinct from those that have been
reported for lysosomal storage disorders (both genetic
and acquired), in as far as EM images thereof are
available in the literature. Lysosomal storage disorders
generally present intra-lysosomal multilayered depositions
(e.g., Fabry) or alternative phenotypes, but do not
resemble the dispersed, dark, fairly uniform aggregates
observed in CINAC/CKDu and several toxic nephropathyKidney International (2020) 97, 1057–1060
